PMV Pharma gets $74M boost for personalized chemistry
P53: "The guardian of the genome." It's not an HBO series, it's a transcription factor implicated in over 50 percent of human cancers. An attractive target, to say the least, which has helped rally a $74M Series B for New Jersey-based PMV Pharma.